EichorEICHOR
Location: Richmond Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Richmond

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Slade Pharmacy · Pfizer · NCT05020236A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part
Phase 1/Phase 2 · VCU · AskBio Inc · NCT05230459Examining Lateralized Aspects of Motor Control Using Non-invasive Neural Stimulation
NA · Virginia Commonwealth University Medical Center · Virginia Commonwealth University · NCT05947279Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Phase 3 · VCU Medical Center · Joseph Broderick, MD · NCT07227246A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 0360005 · Sanofi · NCT06867094Enhancing Oral Cancer Awareness
NA · Virginia Commonwealth University · Virginia Commonwealth University · NCT06682494Genome Transplant Dynamics
Phase N/A · Virginia Commonwealth University · National Heart, Lung, and Blood Institute (NHLBI) · NCT02423070Serological and PCR Testing for COVID-19
Phase N/A · Richmond Research Institute · NCT04404062Randomized Trial of SGLT2i in Heart Transplant Recipients
Phase 4 · Hunter Holmes McGuire VA Medical Center, Richmond, VA · VA Office of Research and Development · NCT06625073Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
NA · Melbourne Pain Specialists · Saluda Medical Pty Ltd · NCT04662905A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Virginia Commonwealth University (VCU) Medical Center ( Site · Merck Sharp & Dohme LLC · NCT06136559Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Virginia Cancer Institute ( Site 0034) · Merck Sharp & Dohme LLC · NCT06393374MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · VCU Massey Comprehensive Cancer Center · National Cancer Institute (NCI) · NCT05564390A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Phase 3 · Bristol-Myers Squibb · NCT06929273A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Phase 3 · VCU Medical Center, Richmond · Vertex Pharmaceuticals Incorporated · NCT04786262Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Phase 1 · Virginia Commonwealth University (VCU) · Ichnos Sciences SA · NCT05862012Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NA · Virginia Common wealth University · Perspectum · NCT04054310His-Bundle Corrective Pacing in Heart Failure
NA · Virginia Commonwealth University · University of Rochester · NCT05265520Enhancing Addiction Treatment Through Psychoeducation
NA · Virginia Commonwealth University · Virginia Commonwealth University · NCT07178158Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Phase N/A · Virginia Commonwealth University · Virginia Commonwealth University · NCT07700225A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
Phase 3 · Local Institution - 0050 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT07424404Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Phase 3 · Children's Hospital of Richmond at Virginia Commonwealth Uni · PedAL BCU, LLC · NCT05183035To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Phase 2 · Aavon Clinical Trials · E-Star BioTech, LLC · NCT06343298A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 2/Phase 3 · VCU Massey Cancer Center at Stony Point · National Cancer Institute (NCI) · NCT05691478A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Phase 3 · Local Institution - 0050 · Bristol-Myers Squibb · NCT07288567Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With P
Phase 2 · Virginia Commonwealth University · Greg Durm, MD · NCT04317534Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · VCU Massey Comprehensive Cancer Center · National Cancer Institute (NCI) · NCT04172532A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Sympt
Phase 4 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT07105111Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · VCU Massey Comprehensive Cancer Center · National Cancer Institute (NCI) · NCT06860594Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Phase 1/Phase 2 · Virginia Commonwealth University · Sangamo Therapeutics · NCT06980948
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.